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ABSTRACT
Objective: This research aims to study the activity of a Streptomyces sp. fermentation product as an antimalarial modality in HepG2 cells.
Methods: The effects of the product against Plasmodium falciparum 3D7 were examined using an in vitro technique parasite. The potency of the 
Streptomyces sp. fermentation product was examined by determining the half maximal inhibitory concentration (IC50), and the mechanism was 
studied using transmission electron microscopy (TEM). Toxicity tests were also conducted.
Results: The Streptomyces sp. fermentation product had an IC50 of 0.001 μg/ml against the parasite, versus values of 0.054 and 0.022 μg/ml for 
quinidine and prodigiosin, respectively. TEM revealed no formation of hemozoin. The Streptomyces sp. fermentation product was non-toxic in HepG2 
cells based on its cytotoxicity concentration 50% of 1.380 μg/ml.
Conclusion: The Streptomyces sp. fermentation product has potential as a potent and non-toxic antimalarial therapy.
Keywords: Antimalarial, Streptomyces sp. Fermentation Product, Half maximal inhibitory concentration, Transmission electron microscopy, Toxicity.
INTRODUCTION
Malaria remains a global health problem, particularly in tropical 
areas [1]. According to Indonesia’s Ministry of Health, the incidence 
of malaria declined between 2011 and 2015 from 1.75 per population 
to 0.85 per population [2]. However, the emergence of antimalarial 
drug resistance has threatened the goal of eradicating malaria [3]. The 
resistance of Plasmodium falciparum to artemisinin has been detected 
in five countries in the Greater Mekong Subregion [4].
Some drugs used to treat malaria are obtained from plants, such as 
quinine and artemisinin. Quinine was initially isolated from the bark 
of the Cinchona tree [4]. Artemisinin was developed from the Chinese 
herb Artemisia annua (qinghao) [5]. Other plant-based substances with 
potent antimalarial effects include the alcoholic extract of the root bark of 
Uapaca nitida (Euphorbiaceae) in Tanzania and extracts from Hernandia 
voyroni (Hernandiaceae) in Madagascar [6]. Research in Iran found that 
extracts from Buxus hyrcana, Erodium oxyrrhnchum, Glycyrrhiza glabra, 
and Ferula oopoda had significant antimalarial activity [7].
Studies have also identified potent antimalarial effects for the 
fermentation products of bacteria. Among them, Baba et al. described 
the antimalarial activity of the fermentation product of the endophytic 
bacterium Streptomyces SUK10 [8]. Boonlarppradab et al. revealed 
that the fermentation products of Saccharopolyspora A and B had 
antimalarial activity with half maximal inhibitory concentration (IC50) 
of 4.1 and 3.9 μM, respectively [9].
Meanwhile, Streptomyces spp. has been widely studied for their antibiotic, 
antifungal, and anticancer activities [10]. Among these, S. griseous was 
the first species to be used in the industrial production of antibiotics [11]. 
In addition, research on the antimalarial effects of Streptomyces spp. has 
also been conducted. Isaka et al. reported that Streptomyces spectabilis 
isolated from soil samples in Thailand exhibited antimalarial activity 
against P. falciparum K1 [12]. Streptomyces spp. can produce various 
secondary metabolites [13,14]. For example, Streptomyces spp. from 
the ocean can produce the secondary metabolite prodigiosin, which has 
confirmed antimalarial effects [15,16].
The alkaloid prodigiosin is a member of the prodiginine family, which has been 
reported to have antibacterial, antifungal, antimalarial, and antiprotozoal 
activity [17]. Papireddy et al. studied prodigiosin, undecylprodigiosin, and 
metacycloprodiginin, finding that all three had potent antimalarial activity, 
with IC50 of 8.0, 7.7, and 1.7 nM, respectively [18]. Lazaro et al. reported that 
heptyl prodigiosin displayed antimalarial activity in vitro [19]. Rahul et al. 
observed that prodigiosin inhibited the formation of Trypanosoma brucei 
gambiense, with an IC50 of 0.158±0.019 g/ml, and exerted antimalarial 
activity with an IC50 of 1.1±5.9 pg/ml in vitro [20]. The spectrum of the 
antifungal activity of prodigiosin is believed to be comprehensive, including 
species of Candida, Aspergillus, Penicillium, Saccharomyces, Cryptococcus, 
and Histoplasma [21]. Prodigiosin reportedly has a mechanism of action 
similar to quinine, namely, inhibiting the formation of hemozoin, which 
can be examined through transmission electron microscopy (TEM). 
TEM is useful in analyzing nearly all cellular components, including the 
cytoskeleton, membrane systems, and organelles [22,23].
Meanwhile, a compound or extract should be tested for toxicity to assess 
its potential harm to living things. Most drugs are metabolized in the 
liver, making HepG2 cells a suitable model to examine their metabolism. 
Therefore, this study used HepG2 cells to assess the efficacy, mechanism 
of action, and potential toxicity of a Streptomyces sp. fermentation 
product against the malaria-causing parasite P. falciparum.
METHODS
Parasite
This study used the P. falciparum 3D7 strain originating from the 
University of Tokyo that is propagated regularly at the Eijkman Institute 
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for Molecular Biology. P. falciparum cells were thawed from liquid 
nitrogen using NaCl and 20% RPMI complete medium. P. falciparum 
3D7 cells were propagated in 10% RPMI complete medium, with 
medium replacement every 2 days. Parasitemia was assessed using thin 
blood smears with Giemsa staining. Cultures of P. falciparum 3D7 that 
caused 2% parasitemia were used to determine IC50.
Drug
The fermentation product of Streptomyces spp. was obtained from 
LIPI. As controls, quinidine and prodigiosin were obtained from the 
Laboratory of Pharmacology, University of Indonesia.
Viability testing
Viability testing was performed using a 96-well plate, with cultures 
of P. falciparum at a volume of 180 ml included in each well. A 20-ml 
stock sample of the Streptomyces sp. fermentation product was added 
to well #12 and then homogenized. A sample was taken from this well, 
introduced into well #11, and homogenized, and this process was 
repeated until well #4 were reached. The dilution method was also 
performed for the quinidine and prodigiosin stocks. The plate was 
incubated in a candle jar at 37 °C for 48 h. Parasitemia was assessed 
by making a thin blood smear stained with 10% Giemsa solution and 
counted under a microscope. A curve of IC50 values was then created 
using the results between the test concentration and the percentage of 
growing parasites.
TEM
P. falciparum 3D7 was incubated with the fermentation products of 
Streptomyces spp. at the IC50 concentration, and untreated controls 
were incubated in a candle jar at 37 °C for 48 h. The samples were then 
diluted with a solution of 2.5% glutaraldehyde (in 0.1 M cacodylate 
buffer + 3% sucrose) and incubated with shaking for 48 h at 4 °C. The 
samples were then washed with 0.1 M cacodylate buffer + 3% sucrose 3 
times. The obtained pellets were incubated in a solution of 2% osmium 
tetraoxide + 2.5% K3Fe(CN)6 and washed 3 times with 0.1 M cacodylate 
buffer + 3% sucrose. The pellets were then dissolved in 10%, 30%, 
50%, 70%, 95%, or 100% ethanol. Pellets were then incubated with 
pure propylene oxide at room temperature for 1 h and centrifuged.
Pellets were then incubated with Spurr’s resin (1:1) at room temperature 
for 30 min and then centrifuged, after which half of the supernatant was 
incubated for 30 min at room temperature and centrifuged. The supernatant 
was then removed, and the pellet was incubated in Spurr’s resin overnight 
under vacuum. Samples were transferred to new tubes. Spurr’s pure resin 
was introduced into each sample, which was incubated under vacuum at 
70°C overnight. Parasite cells were stained using uranium salts.
Toxicity test
HepG2 cell cultures were taken from an −80 °C freezer and thawed. 
The cell suspensions were then introduced into 15-ml Falcon tubes; 
Dulbecco’s Modified Eagle’s medium (DMEM) complete medium 
(DMEM + 1% penicillin-streptomycin + 10% fetal bovine serum) was 
added, and the tubes were centrifuged at 500 rpm for 10 min. For each 
tube, the supernatant was discarded, complete medium was added, 
and the 20-ml sample was placed in 75-cm2 culture flasks. The cultures 
were incubated at 37°C in a 5% CO2 atmosphere, and the medium 
was replaced every 2–3 days. Cells were harvested after approaching 
confluence. Cells were washed with PBS and incubated in 3 ml of 
0.25% trypsin in the incubator for 15 min. Then, complete medium 
was added, and cells were centrifuged at 500 rpm for 10 min. The 
supernatant was discarded, 1 ml of complete medium was added, and 
the number of cells was counted using a hemocytometer. HepG2 cells 
were cultured in 24-well plates at a density of 1 × 105 cells per well. 
After incubation for 24 h, cells were exposed to various concentrations 
of the Streptomyces sp. fermentation product and incubated for 24 
h. The cells were subsequently washed with PBS and incubated in 
0.25% trypsin for 15 min, after which cells were incubated in complete 
medium. The cell suspension was then centrifuged at 500 rpm for 10 
min. The supernatant was discarded, and cells were incubated in 1 ml 
of PBS. Next, 10 ml of the cell suspension was added to 10 ml of Trypan 
blue and then homogenized. Then, 10 ml of this mixture was placed in a 
hemocytometer chamber, and cell viability was calculated. This method 
was also performed for quinidine. The results of cell viability were used 
to determine the cytotoxicity concentration 50% (CC50).
RESULTS
Cell Viability
The inhibitory effects of the Streptomyces sp. fermentation product on 
the growth of P. falciparum 3D7 were examined in comparison to those 
of quinidine and prodigiosin. The IC50 of the fermentation product of 
Streptomyces spp. was 0.001 µg/ml (Table 1 and Fig. 1).
Conversely, the IC50 for quinidine was 0.054 µg/ml (Table 2 and Fig. 2).
In addition, the IC50 for prodigiosin was 0.022 µg/ml (Table 3 and Fig. 3).
TEM analysis of the fermentation product of Streptomyces spp.
The morphology of parasites was examined using TEM at ×8000 
(Fig. 4). In the absence of treatment, the parasite grew normally with 
firm borders and healthy organelles, and hemozoin was produced. 
Table 1: Inhibitory effects of the Streptomyces sp. fermentation 
product on P. falciparum 3D7 growth
Concentration (µg/ml) Parasitemia (%) Parasite growth (%)










P. falciparum: Plasmodium falciparum
Table 2: Growth of P. falciparum 3D7 following exposure to 
quinidine
Concentration (µg/ml) Parasitemia (%) Parasite growth (%)










P. falciparum: Plasmodium falciparum
Table 3: Growth of P. falciparum 3D7 following exposure to 
prodigiosin
Concentration (µg/ml) Parasitemia (%) Parasite growth (%)










P. falciparum: Plasmodium falciparum
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Conversely, when the parasite was exposed to the fermentation product 
of Streptomyces spp., hemozoin was not produced.
Toxicity of the fermentation product of Streptomyces spp. in HepG2 cells 
was evaluated.
The toxicity of the fermentation product of Streptomyces spp. in HepG2 
cells was evaluated using Trypan blue staining. Then, a CC50 curve for 
the fermentation product of Streptomyces spp. relative to the untreated 
controls was created. The toxicity of quinidine was similarly examined. 
At concentrations ≤100 pg/ml, the Streptomyces sp. fermentation 
Fig. 1: The growth curve of Plasmodium falciparum 3D7 following exposure to the Streptomyces sp. fermentation product
Fig. 2: The growth curve of Plasmodium falciparum 3D7 following exposure to quinidine
Fig. 3: The growth curve of Plasmodium falciparum 3D7 following exposure to prodigiosin
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product did not induce significant cytotoxicity (Table 4). Following 
exposure to higher concentrations, the CC50 of the fermentation product 
was calculated as 1.380 µg/ml (Fig. 5).
Conversely, quinidine at a concentration of 200 µg/ml was completely 
cytotoxic to HepG2 cells, whereas cell viability exceeded 50% for 
smaller concentrations (Table 5). After calculating the cell viability 
curve, the CC50 was determined as 160 pg/ml (Fig. 6).
DISCUSSION
Natural products have long been investigated in drug discovery, 
included antimalarial drugs. 45% of clinically used antimalarial drugs 
were derived from natural products [24]. An example is the first 
antimalarial drug, quinine, which was isolated from the bark of the 
Cinchona spp. (Rubiaceae) [6]. In 1972, a group of Chinese researchers 
isolated the antimalarial drug artemisinin from the traditional Chinese 
herb A. annua (Asteraceae) [25]. In addition, Actinomycetes bacteria 
also produce a wide range of bioactive compounds, some of which have 
antimalarial effects [24].
In prior research using S. spectabilis BCC 4785 isolated from soil 
samples, the metabolite metacycloprodigiosin was found to have 
antimalarial activity. Prodigiosin is a secondary metabolite produced 
by Streptomyces and Serratia spp. The Streptomyces sp. fermentation 
product supposedly contains prodigiosin, a secondary metabolite, and 
alkaloid [26]; thus, it might have the same mechanism of action as the 
alkaloids quinine and quinidine. In another study, Lazaro et al. found 
that heptyl prodigiosin has activity similar to quinine against sensitive 
Plasmodium 3D7 [19].
In a previous study, Intaraudom et al., using a crude extract of 
Streptomyces sp. BCC27095 isolated from soil samples in Thailand, 
reported an IC50 of 2.72 µg/ml against a multidrug-resistant P. falciparum 
K-1 strain [27]. Another study using crude extracts of Streptomyces sp. 
BCC26924 reported an IC50 of 0.77 µg/ml against the same strain [28]. 
Meanwhile, Rakotondraibe et al. recorded IC50 of 2.5–10 µg/ml for 
extracts of Streptomyces spp. against P. falciparum Dd2 strains [24]. 
These results illustrate that the fermentation product of Streptomyces 
spp. has good antimalarial activity. However, it must be noted that this 
study used drug-resistant strains, whereas prior research used drug-
resistant Plasmodium spp.
In this study, the fermentation product of Streptomyces spp. appeared 
to have stronger antimalarial activity than the control agents, possibly 
because it contains several secondary metabolites with antimalarial 
effects. Meanwhile, the controls were only single agents. Therefore, 
further research is needed to more closely identify the antimalarial 
agents.
P. falciparum degrades hemoglobin to acquire nutrients for growth. 
This results in increased heme levels, which are toxic to the parasite. To 
overcome this toxicity, the parasite polymerizes heme into hemozoin, 
which is nontoxic. In this study, it appears that hemozoin was not 
formed following exposure to the Streptomyces sp. fermentation 
product, resulting in heme accumulation and death of the parasite.
Fig. 5: The cell viability curve following exposure to the 
Streptomyces sp. fermentation product
Fig. 6: Cell viability curve following quinidine exposure
Table 4: Cell viability following exposure to the fermentation 
product of Streptomyces spp.











Table 5: Cell viability following quinidine exposure







Fig. 4: Morphology of Plasmodium falciparum 3D7 assessed 
through transmission electron microscopy at ×8000 
magnification. (a) In the absence of treatment, hemozoin was 
produced. (b) Hemozoin was not produced when the parasite was 
exposed to the fermentation product of Streptomyces spp.
ba
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Herbs are used as medicines in developing countries based on the 
presence of secondary metabolites [29]. Bacteria such as Streptomyces 
spp. also produce secondary metabolites, and thus, toxicology testing 
is needed to ensure the safe use of fermentation products. The current 
analysis using HepG2 cells indicated that the fermentation product 
should be nontoxic in comparison to the controls.
CONCLUSION
The fermentation product of Streptomyces sp. exhibited potency as 
an antimalarial agent, with an IC50 value of 0.001 µg/ml. The CC50 of 
the fermentation product in HepG2 cells was 1380 µg/ml. The test 
results indicate that the Streptomyces sp. fermentation product exerts 
strong antimalarial effects without causing toxicity, although additional 
research is needed to verify these findings.
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